



[More information about Retina 2027](#)

RETINA 2027

Retina 2027 - Belo Horizonte, April 14 to 17, 2027

Under the historic presidency of **Fernanda Porto and Silvana Vianello** - the first female leadership in 51 years - the International Retina Congress reinvents itself. With an innovative format, cutting-edge technology and science, it will be an unmissable event that will **redefine the future of retina worldwide.**



Dr. Silvana Vianello - President of the Retina BH Congress

"It is an immense honor to welcome you to the 51st BRAVS MEETING - RETINA 2027, in Belo Horizonte. For the first time, we will have a female presidency, led by the two of us, myself and Dr. Fernanda Porto. This historic milestone represents not only an achievement, but the beginning of a new era for our congress, with an innovative, collaborative outlook connected to the future of our specialty."

For this edition, we are preparing a reinvented format, with a new media language and a reach far beyond our horizons. Our goal is to create a unique experience, centered on high-level science, modern technology generating vision, cutting-edge research, and networking and interaction among attendees like never before. **BH awaits you so we can make history together!"**

Dr. Fernanda Belga Ottoni Porto - President of Retina 2027

"In April 2027, Belo Horizonte will be the meeting point of Brazilian and world ophthalmology for **Retina 2027 – the 51st BRAVS Congress** - a gathering that goes far beyond retina. We have prepared a congress for those who believe that the future of retina is built with science, innovation, collaboration and new perspectives. It will be a unique opportunity to reconnect with colleagues, share experiences and be close to some of the great names transforming our specialty."



Brazilian retina will be connected to the world. For the first time, we will welcome **more than 20 SBRV international delegates, coming from different countries, along with speakers and internationally renowned guests.** This global presence expands scientific exchange and reflects a movement we want to strengthen: a retina community that is increasingly connected, collaborative and a leading player on the world stage.

All of this will come together in a beautifully crafted scientific program, with up-to-date content, relevant discussions, innovation, new technologies and room for different perspectives. And we want this to also be an inclusive congress, one that values diversity, participation and the contribution of everyone who helps retina move forward — regardless of generation, background or borders.

And there is something only Belo Horizonte can offer: **our warm Minas Gerais way of welcoming people.** A congress that is welcoming, elegant and surprising, in an exceptional auditorium, with experiences designed to bring people together, spark connections and create lasting memories. I invite you to be part of this historic moment for Brazilian retina. Save the date, secure your spot and come build the next chapters of our specialty with us. The world of retina will be in Belo Horizonte — **and we look forward to having you experience it."**



SOCIETY

BRAVS International Delegates

The internationalization of BRAVS has been part of its journey for nearly a decade. In 2016, during the presidency of André Gomes, a process of institutional engagement began with leading international retina societies and congresses, **including ASRS, EURETINA, and SARyV**. Since then, BRAVS has taken part in international events through case discussion panels and symposia, while also welcoming major delegations and scientific activities from organizations **such as RWC, ASRS, EURETINA, and SARyV** to its annual congress.

Continuing this movement toward greater integration, **BRAVS International Delegates was created**. Coordinated by BRAVS President Dr. Jorge Rocha and International Director Dr. Carlos Augusto Moreira Neto, the initiative aims to strengthen BRAVS' ties with the international retina community and expand opportunities for scientific, academic, and institutional collaboration.

The program brings together retina and vitreous specialists from 21 countries. These highly respected professionals share with us not only their experience and scientific expertise, but also a common desire to build new connections, exchange different perspectives, and strengthen ties within the global retina community.

The initiative includes representatives from Canada, the United States, Mexico, Guatemala, the Dominican Republic, Peru, Bolivia, Paraguay, Argentina, Nigeria, Tunisia, Saudi Arabia, the United Arab Emirates, Portugal, Italy, England, Turkey, Russia, the Philippines, and Japan.

More than an international network, BRAVS International Delegates represents the building of a community founded on scientific excellence, collaboration, friendship, and a shared commitment to advancing the field of retina and preserving vision.

Science knows no borders.

Neither does our mission to fight blindness caused by retinal diseases.

A very warm welcome to BRAVS.

DELEGATES

**Hussein Almuhtaseb**

Qatar

**Aleksandra Rachitskaya**

United States

**Andrea Cardenas**

Guatemala

**Rodrigo Anguita**

United Kingdom

save the date
14 a 17 de abril de 2027
Belo Horizonte - MG



51st BRAVS MEETING
RETINA 2027
April 14-17 | Belo Horizonte - Brazil
PIONEERING HORIZONS
CREATING A NEW VISION

**Pioneering Horizons.
Creating a New Vision.**

Saiba mais em retina2027.com.br



Walid Zbiba

Tunisia



Susana Teixeira

Portugal



Maria Joan Loy

Philippines



Ogugua Okonkwo

Nigeria



Taiji Sakamoto

Japan



Ashish Sharma

India



Daniel Moreno

Mexico



Nassim Abreu

Dominican Republic



Abdullah Alqahtani

Saudi Arabia



Danilo Ianetta

Italy



Olivia Bodivieso

Bolivia



Nur Acar

Turkey



Pablo Cibils

Paraguay



Marcelo Zás

Argentina



David Wong

Canada



Mohammed Amri

United Arab Emirates



Tatyana Avanesova

Russia

Follow SBRV on social media



@retina.sbrv



/retina.sbrv



www.sbrv.org

Members in good standing have full access to:

Exclusive online educational content
Live sessions and webinars
eBooks and digital library
International journals
Scientific area
Retina AI (coming soon)

Congresses and events
Case discussions
National networking
Professional tools
Continuous updates
Certificates and archives

Join BRAVS

Join the largest and most respected retina and vitreous society in Brazil and Latin America!


Become an BRAVS member and **take your medical practice to a new level.**



SCIENCE

Anti-VEGF: 20 years of a revolution that is not over yet

Few interventions have changed the natural history of retinal diseases as profoundly as anti-VEGF therapy. In two decades, we have gone from the pioneering use of intravitreal bevacizumab to agents capable not only of preventing vision loss, but also of restoring vision. More recently, faricimab and aflibercept 8 mg have extended the intervals between injections. Today, the challenge goes beyond potency: **how do we maintain disease control for longer while reducing the burden of injections and visits?**



Listen to the BRAVSCast episode

TKIs: blocking signaling from within

It is in this context that **tyrosine kinase inhibitors (TKIs)** are gaining ground. Unlike conventional anti-VEGF agents, which act in the extracellular space, TKIs block tyrosine kinase activity intracellularly, targeting the signaling involved in angiogenesis. Combined with sustained-release systems, they represent a particularly interesting strategy for increasing treatment durability.

Among the most advanced programs is **DURAVYU™ (EYP-1901)**, which combines the TKI vorolanib with a bioerodible intravitreal implant, designed to provide sustained drug release for months after a single administration. In August 2026, results from the pivotal phase 3 LUGANO study brought an important update. In previously treated patients with neovascular AMD, DURAVYU **did not meet the primary endpoint of non-inferiority in visual acuity** compared with aflibercept 2 mg in the full patient population.

Despite this, the durability data were significant: there was a **42% reduction in treatment burden**, 54% of patients remained free of supplementation through week 56, and 79% received at most one supplementation. Anatomic control was similar to that observed with aflibercept. In an ad hoc analysis excluding nine patients who lost ≥ 15 letters for reasons considered unrelated to neovascular AMD, the non-inferiority criterion was met.

LUGANO therefore brings an important message: **durability needs to go hand in hand with maintaining the functional and anatomic outcomes already achieved by current anti-VEGF agents.** Results from the second pivotal study, LUCIA, expected by the end of 2026, will be key to defining the future of this strategy.

Will durability be the next revolution?

Twenty years ago, we sought to prevent vision loss. Today, we seek to maintain that same control with fewer interventions. In this context, sustained-release TKIs represent one of the most promising strategies of the next generation of treatments. The next anti-VEGF revolution may not simply be a more potent molecule, but rather **a way of keeping our patients seeing well for months with an ever-smaller number of interventions.** The revolution that began two decades ago is still not over. **It has only changed its goal.**

www.sbrv.org

Credits

Editor: Marina Almeida – Professional Registration (MTB) 45725/SP
Graphic design and art editing: Trè Companhia Criativa
Marketing and Commercial: Jéssica Borges

Editorial

Dr. Jorge Rocha: BRAVS President
Dr. Tereza Kanadani: Communications Director
Dr. Denise Marinho: Editorial Support and
Author of the Scientific Article